Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
PHR Stock Forecast 2026-2027
$9.15
Current Price
$565.58M
Market Cap
Buy 11
Hold 8
Sell 0
Wall St Analyst Ratings
Distance to PHR Price Targets
+118.6%
To High Target of $20.00
+53.0%
To Median Target of $14.00
-1.6%
To Low Target of $9.00
PHR Price Momentum
-1.5%
1 Week Change
+4.3%
1 Month Change
-64.7%
1 Year Change
-45.9%
Year-to-Date Change
-72.1%
From 52W High of $32.76
+17.8%
From 52W Low of $7.77
📊 TOP ANALYST CALLS
Did PHR Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Phreesia is one of their latest high-conviction picks.
Latest PHR Stock Price Targets & Analyst Predictions
Based on our analysis of 6 Wall Street analysts, PHR has a bullish consensus with a median price target of $14.00 (ranging from $9.00 to $20.00). The overall analyst rating is Strong Buy (8.0/10). Currently trading at $9.15, the median forecast implies a 53.0% upside. This outlook is supported by 11 Buy, 8 Hold, and 0 Sell ratings.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
PHR Analyst Ratings
11
Buy
8
Hold
0
Sell
PHR Price Target Range
Low
$9.00
Average
$14.00
High
$20.00
Current: $9.15
Latest PHR Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for PHR.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| May 29, 2026 | Truist Securities | Jailendra Singh | Hold | Maintains | $12.00 |
| May 28, 2026 | Citigroup | Daniel Grosslight | Neutral | Maintains | $12.00 |
| May 28, 2026 | Canaccord Genuity | Richard Close | Buy | Maintains | $16.00 |
| May 28, 2026 | DA Davidson | Clark Wright | Buy | Maintains | $14.00 |
| May 20, 2026 | Wells Fargo | Equal-Weight | Downgrade | $N/A | |
| May 15, 2026 | Barclays | Equal-Weight | Downgrade | $N/A | |
| Apr 13, 2026 | Keybanc | Overweight | Maintains | $N/A | |
| Apr 1, 2026 | Citizens | Market Perform | Downgrade | $N/A | |
| Mar 31, 2026 | Citigroup | Neutral | Downgrade | $N/A | |
| Mar 31, 2026 | JP Morgan | Neutral | Downgrade | $N/A | |
| Mar 31, 2026 | Truist Securities | Hold | Downgrade | $N/A | |
| Mar 31, 2026 | Stephens & Co. | Overweight | Maintains | $N/A | |
| Mar 31, 2026 | Canaccord Genuity | Buy | Maintains | $N/A | |
| Mar 31, 2026 | BMO Capital | Outperform | Maintains | $N/A | |
| Mar 31, 2026 | Baird | Neutral | Downgrade | $N/A | |
| Mar 31, 2026 | Needham | Buy | Maintains | $N/A | |
| Mar 26, 2026 | Wells Fargo | Overweight | Maintains | $N/A | |
| Mar 24, 2026 | Mizuho | Outperform | Maintains | $N/A | |
| Feb 20, 2026 | JP Morgan | Overweight | Maintains | $N/A | |
| Jan 23, 2026 | DA Davidson | Buy | Maintains | $N/A |
Phreesia Inc. (PHR) Competitors
The following stocks are similar to Phreesia based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Phreesia Inc. (PHR) Financial Data
Phreesia Inc. has a market capitalization of $565.58M with a P/E ratio of 57.1x. The company generates $495.59M in trailing twelve-month revenue with a 1.9% profit margin.
Revenue growth is +12.9% quarter-over-quarter, while maintaining an operating margin of +5.2% and return on equity of +2.9%.
Valuation Metrics
Market Cap
$565.58M
Enterprise Value
$577.87M
P/E Ratio
57.1x
PEG Ratio
-0.3x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
+12.9%
Gross Margin
+66.9%
Operating Margin
+5.2%
Net Margin
+1.9%
EPS Growth
+12.9%
Financial Health
Cash/Price Ratio
+13.2%
Current Ratio
1.8x
Debt/Equity
25.8x
ROE
+2.9%
ROA
+1.5%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Phreesia Inc. (PHR) Business Model
About Phreesia Inc.
What They Do
Provides patient intake and engagement solutions.
Business Model
The company operates on a subscription-based model, offering healthcare providers a comprehensive platform for patient registration, appointment scheduling, insurance verification, and payment processing. By streamlining administrative workflows, Phreesia enhances operational efficiency and allows providers to focus on patient care, thereby generating recurring revenue through software subscriptions and service fees.
Additional Information
Since its establishment in 2005, Phreesia has been at the forefront of digital transformation in healthcare, responding to the increasing demand for improved patient experiences and operational effectiveness. Its integration capabilities with various health IT systems position it as a key player in supporting outpatient clinics, specialty practices, and hospitals in managing patient interactions.
Company Information
Sector
Healthcare
Industry
Health Information Services
Employees
2,082
CEO
Mr. Chaim Indig
Country
United States
IPO Year
2019
Website
www.phreesia.comPhreesia Inc. (PHR) Latest News & Analysis
Featured Analysis
Powered by
Zacks Investment Research
Are Investors Undervaluing Phreesia (PHR) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Jun 09, 2026
By Zacks Equity Research
Tale of the Tape
Latest News
Quick Summary
A class action lawsuit has been filed against Phreesia, Inc. (NYSE: PHR) for securities violations. Investors who purchased shares between May 8, 2025, and March 30, 2026, should contact Schall Law Firm by July 13, 2026.
Why It Matters
A class action lawsuit against Phreesia for securities violations could impact the company's stock price and investor confidence, affecting potential returns for shareholders.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Phreesia faces claims regarding alleged misrepresentations related to the durability of pharmaceutical marketing commitments in its Network Solutions segment.
Why It Matters
Allegations of misrepresentation in marketing could lead to legal issues or reputational damage for Phreesia, potentially impacting stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bragar Eagel & Squire's Brandon Walker is urging investors who incurred losses in Phreesia (PHR) to reach out for potential legal options.
Why It Matters
The call for investors in Phreesia to discuss losses indicates potential legal action, which could affect stock performance and investor confidence.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Phreesia, Inc. (NYSE: PHR) for alleged securities violations. Affected investors from May 8, 2025, to March 30, 2026, should contact Schall Law Firm by July 13, 2026.
Why It Matters
A class action lawsuit against Phreesia for securities violations could impact the company's stock price, investor confidence, and potential liability, influencing trading decisions.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Faruqi & Faruqi is investigating claims against Phreesia (NYSE: PHR) for investors who lost money between May 8, 2025, and March 30, 2026. A lead plaintiff deadline is set for July 13, 2026.
Why It Matters
The announcement signals potential legal issues for Phreesia, which could impact the stock price and investor confidence. Deadlines for class action participation are crucial for affected shareholders.
Source: Newsfile Corp
Market Sentiment:
Neutral
Quick Summary
A class action lawsuit has been filed against Phreesia, Inc. for alleged federal securities law violations impacting investors from May 8, 2025, to March 30, 2026.
Why It Matters
The class action lawsuit against Phreesia could lead to significant financial liabilities, impacting stock performance and investor sentiment regarding the company's stability and governance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Frequently Asked Questions About PHR Stock
What is Phreesia Inc.'s (PHR) stock forecast for 2026?
Based on our analysis of 6 Wall Street analysts, Phreesia Inc. (PHR) has a median price target of $14.00. The highest price target is $20.00 and the lowest is $9.00.
Is PHR stock a good investment in 2026?
According to current analyst ratings, PHR has 11 Buy ratings, 8 Hold ratings, and 0 Sell ratings. The stock is currently trading at $9.15. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for PHR stock?
Wall Street analysts predict PHR stock could reach $14.00 in the next 12 months. This represents a 53.0% increase from the current price of $9.15. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Phreesia Inc.'s business model?
The company operates on a subscription-based model, offering healthcare providers a comprehensive platform for patient registration, appointment scheduling, insurance verification, and payment processing. By streamlining administrative workflows, Phreesia enhances operational efficiency and allows providers to focus on patient care, thereby generating recurring revenue through software subscriptions and service fees.
What is the highest forecasted price for PHR Phreesia Inc.?
The highest price target for PHR is $20.00 from at , which represents a 118.6% increase from the current price of $9.15.
What is the lowest forecasted price for PHR Phreesia Inc.?
The lowest price target for PHR is $9.00 from at , which represents a -1.6% decrease from the current price of $9.15.
What is the overall PHR consensus from analysts for Phreesia Inc.?
The overall analyst consensus for PHR is bullish. Out of 6 Wall Street analysts, 11 rate it as Buy, 8 as Hold, and 0 as Sell, with a median price target of $14.00.
How accurate are PHR stock price projections?
Stock price projections, including those for Phreesia Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: June 16, 2026 12:22 PM UTC